Officials at Aldevron, which focuses on the production of DNA, RNA, and protein in the genomic medicine space, announced the planned opening of its new Innovation Center in Waltham, MA. The milestone marks a step in Aldevron’s mission to accelerate innovation in genomic medicines while deepening its presence in one of the world’s most dynamic biotech hubs, according to the company.
The new Waltham site is designed to fast-track advancements in the manufacture of DNA, RNA, and proteins for advanced therapies, expanding Aldevron’s capabilities in cell-free DNA, molecular biology, gene editing, and mRNA analytics. By establishing a base in the Boston area, Aldevron is positioning itself at the epicenter of biotech innovation—enabling closer collaboration with clients, faster project timelines and enhanced support for the development of advanced therapies, notes Venkata Indurthi, PhD, CSO.
“Establishing a presence in Waltham puts Aldevron at the crossroads of scientific discovery,” continued Indurthi. “This innovation center is a launchpad for transformative research, empowering us to innovate, collaborate and grow alongside the brightest minds in biotech.”
The Waltham Innovation Center will complement Aldevron’s established scientific teams in Fargo, ND, and Madison, WI, and will serve as a catalyst for recruiting top talent from Boston’s vibrant biotech community, predicted Jennifer Meade, President of Aldevron.
“Our recent role in the groundbreaking ‘Baby KJ’ CRISPR therapy delivery demonstrates the life-changing impact that comes from investing in innovation,” she said. “As one of the most established biotech partners in the U.S., this expansion is a natural evolution—opening new opportunities for growth, deeper client partnerships and greater support for the scientists shaping the future of medicine.”
The post Aldevron Launches New Innovation Center appeared first on GEN – Genetic Engineering and Biotechnology News.
